KDE07704
Colorimetric
Plasma, Serum
Quantitative
78.125 - 5,000 ng/mL
33.12 ng/mL
CV<20%
80-120%
2-8 ℃
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
MILR1444A,PRO301444, CAS: 953400-68-5
Suppression of Il5 and Il13 Gene Expression by Synthetic siRNA Molecules Reduces Nasal Hyperreactivity and Inflammation in a Murine Model of Allergic Rhinitis., PMID:40451198
Clinical and Laboratory Indexes for Predicting Early and Late Responders to Lebrikizumab in Atopic Dermatitis: A Prospective Cohort Observational Study., PMID:40370216
Deciding Which Patients With Atopic Dermatitis to Prioritize for Biologics and Janus Kinase Inhibitors., PMID:40368249
European Guideline (EuroGuiDerm) on atopic eczema: Living update., PMID:40317496
A Case of Cutaneous Fungal Infection Following the Administration of Dupilumab., PMID:40291282
Incidence of upper respiratory tract infections with biological therapies in moderate to severe atopic dermatitis: a systematic review and meta-analysis., PMID:40241901
[Chronic Pruritus: A Review of Its Pathophysiology and Current Treatments]., PMID:40214004
Real-World Japanese Study of the Effectiveness and Safety of Switching From Dupilumab to Lebrikizumab in Patients with Moderate to Severe Atopic Dermatitis., PMID:40202458
Real-world experience of switching from tralokinumab to lebrikizumab in atopic dermatitis., PMID:40130939
24-Week Real-World Effectiveness and Safety of Lebrikizumab for Atopic Dermatitis in Japan: An Analysis Stratified by Prior Systemic Therapy., PMID:40098530
Investigating Efficacy of Atopic Dermatitis Systemic Therapeutics After Discontinuation Part I: Biologics., PMID:40078859
Performance characterization of spring-actuated prefilled pen devices for lebrikizumab and dupilumab., PMID:40053331
Emerging treatments for dermatologic diseases in infants, children, and adolescents: a systematic review of clinical trials on biologics and small molecule inhibitors., PMID:40042725
Real-World Effectiveness and Safety of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis: A 16-Week Study in Japan., PMID:39977111
Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis: Network Meta-analysis of Efficacy., PMID:39953372
Comparison chart: Interleukin (IL) receptor antagonists for atopic dermatitis., PMID:39946701
Nemolizumab (Nemluvio) for atopic dermatitis., PMID:39946696
Rosacea-like skin reaction under treatment with dupilumab for atopic dermatitis., PMID:39870387
Lebrikizumab decreases type 2 inflammatory biomarker levels in patients with asthma: data from randomized phase 3 trials (LAVOLTA I and II)., PMID:39781908
Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis., PMID:39761965
The efficacy of longer-term lebrikizumab treatment in patients with moderate-to-severe atopic dermatitis who did not meet protocol-defined response criteria at week 16 in 2 randomized controlled clinical trials., PMID:39733939
Advanced Biologic Therapies in the Management of Asthma in Children and Adolescents: A Comprehensive Network Meta-Analysis., PMID:39709955
Improved quality of life in patients treated with lebrikizumab monotherapy is mediated by improvements in itch and sleep: results from two phase III trials in patients with moderate-to-severe atopic dermatitis., PMID:39680511
Lebrikizumab: a new anti-IL-13 agent for treating moderate-to-severe atopic dermatitis., PMID:39641601
Evaluation of Pharmacokinetics of Lebrikizumab in Healthy Individuals After Subcutaneous Administration Using a Prefilled Syringe or Autoinjector in a Phase 1 Randomized Study., PMID:39638723
Correction to: Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2)., PMID:39636571
Efficacy and safety of lebrikizumab for the treatment of moderate-to-severe atopic dermatitis: a systematic review and meta-analysis., PMID:39629076
Efficacy and safety of lebrikizumab combined with topical corticosteroids in Japanese patients with moderate-to-severe atopic dermatitis: a phase 3, double-blind, placebo-controlled, randomized clinical trial (ADhere-J)., PMID:39625230
Biologics in allergology and clinical immunology: Update on therapies for atopic diseases, urticaria, and angioedema and on safety aspects focusing on hypersensitivity reactions., PMID:39600395
Atopic Dermatitis-Related Problems in Daily Life, Goals of Therapy and Deciding Factors for Systemic Therapy: A Review., PMID:39598368
Comparative efficacy of targeted systemic therapies for pruritus in moderate-to-severe atopic dermatitis without topical treatment: a network meta-analysis., PMID:39592133
Lebrikizumab-lbkz., PMID:39561252
IL-13 inhibition in the treatment of atopic dermatitis - new and emerging biologic agents., PMID:39558725
[Not Available]., PMID:39551509
Lebrikizumab (Ebglyss) for atopic dermatitis., PMID:39509156
The Pathophysiology, Diagnosis and Management of Chronic Inflammatory Skin Diseases., PMID:39463216
Long-term management of moderate-to-severe atopic dermatitis with lebrikizumab and concomitant topical corticosteroids: a 68-week randomized double-blind placebo-controlled phase III trial in Japan (ADhere-J)., PMID:39442013
Publisher Correction: Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment., PMID:39424713
Current and Emerging Biologics for Atopic Dermatitis., PMID:39389711
Lebrikizumab approval for the treatment of moderate to severe atopic dermatitis in Italy., PMID:39325369
Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2)., PMID:39249591
Lebrikizumab Combined with Topical Corticosteroids Improves Patient-reported Outcomes in Japanese Patients with Moderate-to-severe Atopic Dermatitis., PMID:39248292
An expert consensus on managing dupilumab-related ocular surface disorders in people with atopic dermatitis 2024., PMID:39236226
Biologic and Small Molecule Therapy in Atopic Dermatitis., PMID:39200305
Extended Half-life Antibodies: A Narrative Review of a New Approach in the Management of Atopic Dermatitis., PMID:39147994
Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment., PMID:39123054
Safety and efficacy of biologic drugs in children or adolescents with atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials., PMID:39101303
Order: order@antibodysystem.com
Mail: support@antibodysystem.com
For research use only. Not for human or drug use.
Find out more about placing an order here
